Two sessions a week, and the evidence behind the prescription
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
STEP programme
Page 6 of 18 of this archive, newest first.
TRIUMPH-1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SUSTAIN-6 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
TRIUMPH-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Eating enough protein on a suppressed appetite is an arithmetic problem before it is a nutritional one
The resistance-training and energy-deficit literature supports a higher protein intake. None of it was conducted in people taking an incretin.
Load, not cardio: the distinction the general advice keeps losing
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
PIONEER 6 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURPASS-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The supplement trade found this drug class quickly, and the citations did not improve
A survey of what the meta-analyses support, with the populations named.
FLOW extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURPASS-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURPASS-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The shortage years, and what they taught about interruption
Why the reason for stopping changes what happens afterwards.
STEP 1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SELECT misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Side effects, cost, supply, target: four reasons with four trajectories
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURPASS-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.